Trial Profile
An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Hydrocortisone (Primary)
- Indications Adrenal insufficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors DuoCort; Shire; ViroPharma Incorporated
- 19 May 2017 New trial record
- 14 Mar 2017 Results published in the European Journal of Endocrinology